Korea’s bio and pharmaceutical industry is expanding rapidly, supported by robust biosimilar capabilities, world-class CDMO capacity, and advanced clinical trial infrastructure. As of 2023, the market size reached KRW 31.45 trillion, ranking 13th globally. Export momentum strengthened in 2024 and 2025, driven by rising European demand for biosimilars and increased shipments of medical devices such as implants and ultrasound imaging systems.
Industry leaders are accelerating global expansion. Celltrion’s merger streamlined commercialization and distribution while boosting U.S. production capacity. Samsung Biologics continues its large-scale CDMO expansion with its 5th plant in operation and 6th under planning, backed by significant global contracts and growing pipelines in ADC and GLP-1 therapies. Samsung Bioepis, Yuhan, and other major players are strengthening their presence in overseas markets through new launches and regulatory approvals. Korea also benefits from geopolitical and regulatory shifts. Potential restrictions on U.S.–China bio cooperation may create additional opportunities for Korean CDMO companies. Meanwhile, Seoul now ranks 2nd globally in clinical trial infrastructure, supported by rapid approval timelines, highly skilled talent, and advanced medical systems—reinforcing Korea’s position as a preferred hub for global clinical development.
Looking ahead, the sector is expected to maintain strong growth driven by high-value therapeutic pipelines, expansion of overseas manufacturing capabilities, and continued global demand for biosimilars.
Key Summary
-
KRW 31.45T market size, 13th largest globally
-
Strong rebound in exports led by biosimilars
-
Celltrion merger accelerates global commercialization
-
Samsung Biologics expanding CDMO capacity with 5th & 6th plants
-
Seoul ranks 2nd globally in clinical trial infrastructure
-
Growth in ADC, GLP-1 and other high-value biopharma pipelines
Contacts
